Dewmar International BMC, Inc. (DEWM) Files Paperwork with the United States Patent and Trademark Office
24 Luglio 2017 - 6:14PM
InvestorsHub NewsWire
July 24, 2017 11:49 ET
Dewmar International BMC, Inc. (DEWM) Files Paperwork with the
United States Patent and Trademark Office to Secure Intellectual
Property Related to Cannabinoids and Parkinson's Disease
New provisional patent will advance Dewmar's
intellectual property assets related to Cannabinoids and is a
follow up to last week's USPTO filing for lung cancer
NEW ORLEANS, LA--(NewMediaWire - Jul 24, 2017)
- Dewmar International BMC, Inc. (OTC PINK: DEWM)
today announced that it has filed documents with the United States
Patent and Trademark Office for the treatment of Parkinson's
disease with cannabinoids.
Medical Marijuana has over 100 molecules or cannabinoids within
the plant that in the right combinations or using the right
delivery methods, can be used to treat anything from cancer to
Parkinson's disease. It is Dewmar's goal to utilize the experience
and the education of its CEO, Marco Moran DPh, MBA to
commercialize its intellectual property assets related to marijuana
and most importantly, the precise delivery of medical marijuana and
its constituents and/or byproducts to bring a new era in targeted
therapeutics to improve patient care and outcomes.
Parkinson's disease is a progressive disorder of the nervous
system that affects movement. The disease is chronic and
progressive which means that it is always with you, cannot be
cured, and it gets worse over time. No one knows exactly what
causes Parkinson's disease but in short, some brain cells in the
human brain produce a chemical called dopamine. Dopamine is a
chemical that relays messages to control movements of the human
body. When enough of the dopamine-producing cells are damaged, the
symptoms of Parkinson's disease begin to appear.
Marco Moran, CEO of Dewmar International, commented, "Research
suggests two problems persist with medicines used to treat
Parkinson's disease today; 1) low metabolic absorption of the
medicine by the human body and 2) severe side effects. Cannabinoids
may prove to be more effective in some instances with fewer side
effects when compared to common medicines used to treat Parkinson's
disease. So, our goal is to utilize our patent pending technology
to deliver effective cannabinoids to Parkinson's patients with a
rapid onset of action and high bioavailability. This is the essence
of the intellectual property that we are seeking to
protect."
About Dewmar International BMC, Inc.
Dewmar International BMC, Inc. is a certified service-disabled
veteran business concern, new product development, manufacturing
and brand management company. Established in 2003, Dewmar's primary
business strategy has been in creating high profit margins with
functional foods and beverages, such as Lean Slow Motion
Potion™, the longest selling relaxation drink in Walmart;
and Kush Cakes™ that is rated as the top selling
relaxation brownie in the U.S. market today. The company has
offices in Clinton, MS; Houston, TX; Denver, CO and New Orleans,
LA.
Follow Dewmar on its
official Facebook and Twitter sites where the
CEO is inclined to provide information, sometimes on a daily basis,
about some of the Company's current activities and key staff
activities. Also, subscribe to our Company Newsletter on
the bottom right of our homepage on our website to
receive updates as well.
Click here for the Safe Harbor Statement.
CONTACT INFORMATION
Dewmar International BMC, Inc.
Investment & Company Information
InvestorRelations@DewmarInternational.com
Grafico Azioni Dewmar International BMC (CE) (USOTC:DEWM)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Dewmar International BMC (CE) (USOTC:DEWM)
Storico
Da Dic 2023 a Dic 2024